SCHOFIELD, Wis., Dec. 9, 2009 (GLOBE NEWSWIRE) -- PuraMed BioScience (OTCBB:PMBS) announced today that it has recently scheduled air time for its first national direct response commercial featuring LipiGesic(TM) M, the Company's non-prescription medication for migraine headaches.
The 120-second spot is scheduled to begin airing on the week of Dec. 14 in select national test markets, and will continue testing for four to six weeks. The commercial will appear on several national cable networks, such as WE tv, a network with 72 million viewers, and others that appeal to an identified target demographic for LipiGesic(TM) M.
PuraMed BioScience is a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines that treat migraine headaches, insomnia and tension-type headaches under the brand name LipiGesic(TM).
PuraMed's commercial was produced by Avalanche Creative Services, Inc. of New York City. Avalanche has successfully created and produced over 100 direct response television commercials for nutritional supplement clients in the past six years that have collectively generated over $300 million worth of revenue.
"We look forward to airing our first direct response commercial next week for LipiGesic(TM) M," said PuraMed BioScience CEO Russell Mitchell. "These national network tests will help us to best identify who is purchasing our product and analyze their experience. In addition, it will be the first time that PuraMed begins to generate revenue. After the tests, we can then go forward with a more expansive campaign utilizing the most effective direct response strategy to raise awareness and revenue."
The commercial is available for viewing on the corporate website at www.PuraMedBioScience.com. Click on the "Investor" tab, then the "Promotional Media" tab to view.
In addition to calling the toll-free number in the commercial to purchase LipiGesic(TM) M, orders can be placed through PuraMed's new e-commerce website, www.MyMigraineGone.com.
About the Company:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic(TM) M, which provides acute relief from migraine headaches; the Company also has plans to launch LipiGesic(TM) PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic(TM) H for common tension headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at www.twitter.com/puramed.
Forward Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.